M&A Deal Summary |
|
---|---|
Date | 2019-05-01 |
Target | Pernix Therapeutics Holdings |
Sector | Life Science |
Buyer(s) | Currax Pharmaceuticals |
Deal Type | Add-on Acquisition |
Deal Value | 76M USD |
Advisor(s) | Guggenheim Securities Ernst & Young Capital Advisors LLC (Financial) Davis Polk & Wardwell (Legal) |
SEARCH BY
Try For Free 7-Day Free Trial
Currax Pharmaceuticals LLC is a specialty pharmaceutical business focused on acquiring and commercializing prescription drugs within the U.S. market. Currax distributes a range of both Branded and generic pharmaceutical products, including Silenor®, Treximet®, Zohydro® ER with BeadTek® and the authorized generic of Treximet®.
DEAL STATS | # |
---|---|
Overall | 1 of 2 |
Sector (Life Science) | 1 of 2 |
Type (Add-on Acquisition) | 1 of 2 |
State (New Jersey) | 1 of 1 |
Country (United States) | 1 of 2 |
Year (2019) | 1 of 2 |
Size (of disclosed) | 1 of 1 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2019-09-27 |
Nalpropion Pharmaceuticals
San Diego, California, United States Nalpropion Pharmaceuticals, Inc. is a biopharmaceutical company focused on the treatment of weight loss. Nalpropion Pharmaceuticals was formed in 2018 and is based in San Diego, California. |
Buy | - |